Artera is set to make a significant impact at the ASTRO 2025 Annual Meeting with four groundbreaking abstracts that underscore the potential of AI in revolutionizing cancer diagnostics. These presentations not only highlight the successful validation of the ArteraAI Prostate Test in diverse populations but also reinforce the company’s commitment to advancing personalized cancer care through innovative technology.
SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO). The presentations collectively showcase Artera’s vision to advance the frontier of personalized cancer care, including the first validation of the ArteraAI Prostate Test in an Asian patient cohort; the rapid development and validation of its MMAI bio
Source: Original Press Release
